Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe STEP 1 trial, which tested semaglutide 2.4mg in adults with obesity, paired the medicine with a reduced-calorie diet and increased physical activity — not the medicine alone. Average weight reduction reached around 15% over 68 weeks under those combined conditions. Exercise was part of the protocol from the start, which tells you something important about how Wegovy is designed to be used. That said, working out on a GLP-1 medicine raises real practical questions: how hard, how often, what type, and what happens when nausea gets in the way. This page answers those questions using the available clinical guidance, so you can get the most from treatment without guessing.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial, published in the New England Journal of Medicine, enrolled 1,961 adults with a BMI of 30 or above (or 27-plus with at least one weight-related condition) and randomised them to semaglutide 2.4mg or placebo. Both groups received support to reduce calorie intake and increase activity. The semaglutide group lost an average of around 15% of body weight at 68 weeks; the placebo group lost roughly 2.4%. The point is not just the headline figure, it is that physical activity was a defined component of the intervention from day one.
Official UK guidance reflects this. NHS England's guidance on weight-management injections describes semaglutide as a medicine used alongside lifestyle changes including diet and physical activity. Clinical trials do not treat exercise as a nice-to-have; they build it into the design. If you want outcomes that match what trials reported, the activity component is part of the deal.
None of this means you need to become a gymgoer overnight. The guidance does not specify a minimum step count or a particular sport. What it does establish is the direction: more movement, progressively, at a pace that suits your current capacity. That is a sensible starting point whether you are on week two of 0.25mg or six months into maintenance dose.
Weight loss from any effective intervention (GLP-1 medicines included) brings down both fat mass and lean mass. Lean mass matters because muscle is metabolically active tissue: it burns energy at rest, supports joints, and underpins the kind of functional strength that makes everyday life easier. Studies in people using GLP-1 receptor agonists suggest that a meaningful proportion of lost weight can come from lean tissue if resistance training is absent.
The practical implication is that your plan for using Wegovy should include some form of resistance work, not necessarily heavy barbell training, but exercises that challenge the muscles to adapt. Bodyweight squats, resistance bands, light dumbbells, or swimming all count. Two sessions a week is a reasonable target for most people starting out; three or four as fitness builds.
Protein intake matters alongside this. When appetite is suppressed, it becomes easier to eat too little protein without noticing. Prioritising protein at each meal (eggs, fish, lean meat, legumes, dairy) helps protect muscle while the calorie deficit does its work. Exact targets depend on your weight, activity level and any existing health conditions, so a prescriber or dietitian is better placed than a webpage to give you a personal number.
If you are curious about how other patients structure their broader weight-loss plan while on semaglutide, that is worth reading alongside this page.
Nausea, fatigue and occasional dizziness are the most commonly reported side effects in the early weeks of semaglutide treatment and after each dose step. They typically ease within days to a couple of weeks as the body adjusts, but they can make exercise feel genuinely difficult in the short term.
This is where a rigid training plan tends to break down. The more useful approach is to keep moving at whatever intensity feels manageable, a 20-minute walk on a nauseous morning is not failure, it is good judgement. Dehydration compounds GI symptoms, so hydration before and during exercise is worth paying attention to. Heavy high-impact sessions on an empty or unsettled stomach are likely to make nausea worse; lighter aerobic work, yoga or walking tend to be better tolerated.
If you are looking at how to fit other practical considerations into your routine (including what happens when travel disrupts your schedule) there is separate guidance on taking Wegovy on a plane that covers storage and logistics. Keeping your pen correctly refrigerated matters even around gym sessions; refer to the Patient Information Leaflet for the precise room-temperature window.
Worth knowing: GLP-1 medicines slow gastric emptying, which can affect blood sugar response during prolonged exercise. Most people on Wegovy for weight management will not experience hypoglycaemia, but if you have type 2 diabetes or take other diabetes medicines alongside it, discuss your exercise plans with your prescriber before pushing intensity up significantly.
A useful structure for most people starting Wegovy combines three types of movement: daily low-intensity activity (walking, cycling, anything that gets you out of a chair), two to three sessions of cardiovascular exercise per week at moderate intensity, and two resistance sessions. That is not a prescription, it is a framework to adapt.
Start where you are. If your current level is sedentary, adding 20 minutes of walking each day is a meaningful change; it does not need to be a five-day gym programme in week one. Progress gradually, especially in the first month when the medicine itself is adjusting your appetite and energy levels.
Thinking about what to eat alongside your Wegovy treatment is closely connected to how exercise goes, under-fuelled workouts on a reduced appetite are a common stumbling block. The broader question of what different Wegovy treatment plans involve is worth considering too, especially if you are still deciding whether this route is right for you.
For anyone weighing up how semaglutide compares to other options, our semaglutide overview and the Wegovy treatment page cover the licensed evidence in full. If cost is part of your thinking, the Wegovy cost page sets out what private treatment typically involves in the UK. And if you are ready to talk to a prescriber about whether Wegovy is clinically appropriate for you, our free consultation is the right next step, a named prescriber, not software, reviews your answers the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.